Cancer, Crypto, and a $100M Gamble: Will Propanc’s Bet Pay Off? 🚀💊

by

Well, strap in, folks, because Australia-based Propanc Biopharma has decided that the best way to fight cancer is to throw $100 million into a crypto treasury. 🤑 Yes, you read that right. A company that’s supposed to be saving lives is now moonlighting as a crypto bro. Their CEO, James Nathanielsz, called this move “transformative,” which is just a fancy way of saying, “We’re rolling the dice and hoping Bitcoin doesn’t crash again.” 🎲

Here’s the deal: Propanc got an initial $1 million from Hexstone Capital, a family office that apparently has a soft spot for biotech companies with a side hustle in crypto. Over the next 12 months, they could get up to $99 million more. Because nothing says “cancer research” like convertible preferred stock and digital assets. 📈

The plan? Use the cash to build a crypto treasury and speed up the development of their cancer therapy, PRP, which is set to enter human trials in 2026. Because if there’s one thing cancer patients need, it’s for their treatment to be funded by the same stuff that’s causing your nephew to yell about Dogecoin at Thanksgiving. 🦃

Nathanielsz is bullish, of course. He says their proenzyme therapy could target not just metastatic cancer but also chronic diseases. Which is great, except now their fate is tied to the whims of the crypto market. Good luck explaining that to your investors when Ethereum dips 30% overnight. 📉

“We can target not only patients suffering from metastatic cancer from solid tumors, but several chronic diseases based upon the mechanism of action of proenzyme therapy.” 🧬✨

Propanc hasn’t said which cryptocurrencies they’ll buy, but Hexstone’s clients have dabbled in everything from Bitcoin to Injective. So, basically, they’re putting their money where the blockchain is. Let’s just hope it’s not on a rug pull. 🪙

Biotech Meets Crypto: A Match Made in… Somewhere

Propanc isn’t alone in this bizarre trend. Sonnet BioTherapeutics and Sharps Technology have also jumped on the crypto bandwagon, presumably because traditional investors were like, “Nah, we’re good.” But here’s the kicker: Propanc’s investors are not having it. Their shares plunged 10.5% on Monday. Ouch. 😬

Crypto and biotech, sitting in a tree, losing money together

Crypto Treasuries: The New Pet Rock? 🪨

Meanwhile, Bitcoin treasury holding companies are losing their luster faster than a fidget spinner in 2018. Even Strategy, the biggest player, has seen its market cap shrink by 43% since July. So, Propanc’s timing? Immaculate. 🤦‍♂️

In conclusion, if you’re a cancer patient, a crypto enthusiast, or just someone who enjoys watching companies make questionable decisions, this is your moment. Popcorn not included. 🍿

Read More

2025-11-11 03:01